Answers are grounded in this paper and cite their sources.
Failure to achieve unassisted arteriovenous fistula (AVF) maturation remains a common challenge in hemodialysis patients. This study aimed to develop and internally validate an exploratory prediction model for failure to achieve unassisted AVF maturation using routinely available preoperative clinical and laboratory variables. We retrospectively analyzed 160 patients undergoing first-time AVF creation. The primary endpoint was an operational composite endpoint reflecting failure to achieve unassisted AVF maturation. It comprised failure to meet clinical and ultrasound maturation criteria by 12 weeks or receipt of a qualifying maturation-promoting intervention within 12 weeks and before first successful AVF use. Multivariable logistic regression was used for model development. Model performance was assessed using discrimination, calibration, and exploratory decision-curve analysis. Internal validation was performed using complete-pipeline bootstrap resampling with 1000 replicates. The primary endpoint, defined as an operational composite of failure to achieve unassisted maturation, occurred in 58 of 160 patients (36.2%). Among the 58 patients meeting the composite endpoint, 55 did not meet the predefined maturation criteria and had no documented maturation-promoting intervention before outcome classification, whereas 3 underwent a maturation-promoting intervention within 12 weeks and before first successful AVF use. Monocyte percentage (odds ratio [OR] = 1.61, 95% confidence interval [CI] 1.31–1.98) and albumin (OR = 0.84, 95% CI 0.77–0.91) were independently associated with the endpoint. The combined model had an apparent area under the receiver operating characteristic curve (AUC) of 0.811 and an optimism-corrected AUC of 0.787. A sensitivity analysis excluding the 3 intervention cases yielded virtually identical results (OR 1.60 and 0.85; AUC 0.808). However, calibration assessment identified residual miscalibration (Hosmer-Lemeshow P = 0.002), and the Youden-derived threshold of 0.328 should be considered exploratory and is not recommended for clinical decision-making. Monocyte percentage and albumin were associated with failure to achieve unassisted AVF maturation in this retrospective cohort. The model showed moderate internal discrimination, but residual miscalibration, limited sample size, and potential model-selection optimism restrict interpretation. External validation is required before clinical use.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: